PDF(Sci-hub)
Abstract：
In this review, we discuss about current knowledge about stem cell (SC) therapy in the treatment of retinal degeneration. Both human embryonic stem cell and induced pluripotent stem cell has been growth in culture for a long time, and started to be explored in the treatment of blinding conditions. The Food and Drug Administration, recently, has granted clinical trials using SC retinal therapy to treat complex disorders, as Stargardt\'s dystrophy, and patients with geographic atrophy, providing good outcomes. This study\'s intent is to overview the critical regeneration of the subretinal anatomy through retinal pigment epithelium transplantation, with the goal of reestablish important pathways from the retina to the occipital cortex of the brain, as well as the differentiation from pluripotent quiescent SC to adult retina, and its relationship with a primary retinal injury, different techniques of transplantation, management of immune rejection and tumorigenicity, its potential application in improving patients\' vision, and, finally, approaching future directions and challenges for the treatment of several conditions.
摘要：
在这次审查中,我们讨论了有关干细胞（SC）治疗视网膜变性的最新知识。人胚胎干细胞和诱导多能干细胞都在培养物中生长了很长时间,并开始探索盲症的治疗方法。食品和药物管理局,最近,已批准使用SC视网膜疗法治疗复杂疾病的临床试验，作为Stargardt的营养不良,和有地理萎缩的病人，提供良好的结果。本研究的目的是概述视网膜下解剖的关键再生通过视网膜色素上皮移植,目的是重建从视网膜到大脑枕骨皮质的重要途径，以及从多能静止SC到成人视网膜的分化，以及它与原发性视网膜损伤的关系，不同的移植技术，免疫排斥和致瘤性的管理，其在改善患者视力方面的潜在应用，and,最后,探讨未来治疗几种疾病的方向和挑战。
